Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

The stock's fall snapped a two-day winning streak.

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that it has extended and expanded its partnership with Bristol Myers ...

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.